Dyax Stock Price, News & Analysis (NASDAQ:DYAX)

$38.41 0.00 (0.00 %)
(As of 12/17/2017 07:02 AM ET)
Previous Close$38.41
Today's RangeN/A
52-Week Range$14.06 - $38.56
VolumeN/A
Average Volume5.25 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Dyax (NASDAQ:DYAX)

Dyax logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Receive DYAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DYAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:DYAX
CUSIP26746E10
Phone+1-617-2505769

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.21)
Net IncomeN/A
Net Margins-47.32%
Return on Equity-14.86%
Return on Assets-12.09%

Miscellaneous

EmployeesN/A
Outstanding Shares146,360,000

Dyax (NASDAQ:DYAX) Frequently Asked Questions

What is Dyax's stock symbol?

Dyax trades on the NASDAQ under the ticker symbol "DYAX."

How were Dyax's earnings last quarter?

Dyax Corp. (NASDAQ:DYAX) announced its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analysts' expectations of $24.96 million. Dyax had a negative net margin of 47.32% and a negative return on equity of 14.86%. The business's revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm earned ($0.01) earnings per share. View Dyax's Earnings History.

Who are some of Dyax's key competitors?

How do I buy Dyax stock?

Shares of Dyax can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dyax's stock price today?

One share of Dyax stock can currently be purchased for approximately $38.41.

How can I contact Dyax?

Dyax's mailing address is 55 Network Dr, BURLINGTON, MA 01803-2756, United States. The biopharmaceutical company can be reached via phone at +1-617-2505769.


MarketBeat Community Rating for Dyax (DYAX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about Dyax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dyax (NASDAQ:DYAX) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Dyax (NASDAQ:DYAX) Earnings History and Estimates Chart

Earnings by Quarter for Dyax (NASDAQ:DYAX)

Dyax (NASDAQ DYAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.05)($0.05)$13.65 million$14.12 millionViewN/AView Earnings Details
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Dyax (NASDAQ:DYAX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Dyax (NASDAQ:DYAX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dyax (NASDAQ DYAX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Dyax (NASDAQ:DYAX)
Institutional Ownership by Quarter for Dyax (NASDAQ:DYAX)

Dyax (NASDAQ DYAX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dyax (NASDAQ DYAX) News Headlines

Source:

SEC Filings

Dyax (NASDAQ:DYAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dyax (NASDAQ:DYAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dyax (NASDAQ DYAX) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.